Beneficial Effects of Control-IQ Automated Insulin Delivery in Basal-Bolus and Basal-Only Insulin Users With Type 2 Diabetes.

Carol J Levy,Dan Raghinaru,Yogish C Kudva,Keta Pandit,Thomas Blevins,Luis Casaubon,Donna Desjardins,Camilla M Levister,Grenye O'Malley,Corey Reid,John Lum,Craig Kollman,Roy W Beck

Clinical Diabetes（2023）

引用 1|浏览9

暂无评分

摘要

The t:slim X2 insulin pump with Control-IQ technology (Control-IQ) advanced hybrid closed-loop automated insulin delivery system was evaluated in this prospective single-arm trial. Thirty adults with type 2 diabetes using the Control-IQ system showed substantial glycemic improvement with no increase in hypoglycemia. Mean time in range (70-180 mg/dL) improved 15%, representing an increase of 3.6 hours/day, and mean glucose decreased by 22 mg/dL.

查看译文

关键词

insulin users,diabetes,basal-bolus,basal-only

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要